BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Everest Medicines Acquires CARDAMYST Rights To Strengthen Cardiovascular Portfolio In Greater China

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...

March 24, 2026 | News

Belief BioMed And Grand Life Sciences Forge Exclusive Pact To Advance Hemophilia A Gene Therapy

Belief BioMed ("BBM") and Grand Life Sciences Group Co., Ltd. ("Grand Life Sciences") today announced an exclusive collaboration agreement. Under the agree...

March 24, 2026 | News

Taiwan Strengthens Its Position In Asia’s Next Phase Of Bioprocessing Growth

Taiwan’s bioprocessing and biotechnology sector has moved from a predominantly research-and-services footing toward a more industrialised, globally c...

March 20, 2026 | Analysis

Taiwan Bio And Terumo BCT Advance Automated Treg Manufacturing With Quantum Flex Platform

Taiwan Bio will leverage the Quantum Flex™ Cell Expansion System 3-in-1 workflow beyond CAR-T to support&nb...

March 19, 2026 | News

Locus Cell And Charles River Sign Strategic MoU To Advance Cell And Gene Therapy Manufacturing In APAC

Locus Cell Co., Ltd. ("Locus Cell"), a Taiwan-based cell and gene therapy (CGT) Contract Development and Manufacturing Organization (CDMO), and Charles Riv...

March 13, 2026 | News

Vaxcellbio And Reber Genetics Form Strategic Partnership To Expand Companion Animal Immunotherapy Across Asia

Vaxcellbio (CEO Je-Jung Lee, MD, PhD), a leading immuno-oncology company, announced on Wednesday that it has signed a Master Partnership Agreement (MPA) wi...

March 12, 2026 | News

Insilico Medicine AI Discovered CKD Anemia Drug ISM4808 Enters Phase I Clinical Trial

Insilico Medicine (Insilico Medicine, HKEX: 03696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), announced th...

March 09, 2026 | News

Senhwa Biosciences And CellType Partner To Advance AI Driven Development Of CX 4945 Cancer Therapy

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and inf...

March 05, 2026 | News

Formosa Pharmaceuticals Signs Exclusive Licensing Agreement With Arrotex For APP13007 In Australia And New Zealand

Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Arrotex Ph...

February 24, 2026 | News

Jyong Biotech Strengthens Preventive Medicine Position With Positive Phase II Data And Asian Expansion

Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modul...

February 16, 2026 | News

HanchorBio Secures FDA Orphan Drug Designation For HCB101 In Gastric Cancer

First SIRPα-IgG4 Fc Fusion Protein Granted Orphan Status in Gastric Cancer HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnolog...

February 16, 2026 | News

WuXi Biologics And HanchorBio Inc. Sign Strategic Collaboration To Advance Next Generation Fusion Biologics

WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a globa...

January 27, 2026 | News

Formosa Pharmaceuticals Secures Strategic Korea Commercial Partner For Its FDA Approved Ophthalmic Therapy

Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Sam...

January 13, 2026 | News

Nuclera Secures First Commercial Sales In Asia With Landmark Installations In Taiwan

Installations at National Taiwan University and National Cheng Kung University expand Nuclera’s global footprint with first commercial sales in Asi...

January 08, 2026 | News

Stay Connected